Abstract
Upper gastrointestinal (GI) ulceration from drugs and stress, as well as inflammatory bowel diseases (IBD) are relatively common GI pathologies which have an appreciable morbidity and mortality. Furthermore, the role of environmental, genetic and nutritional factors in the aetiology of various cancers and other GI disorders emphasizes the importance of research into these and other GI conditions. Each of these pathologies has multiple mechanisms. Recent studies examining the effects of these agents or conditions on the development of acute GI ulceration have highlighted: (1) vascular injury and factors mediating this, among them eicosanoids, endothelins and nitric oxide, (2) leucocyte adhesion, infiltration and activation, (3) neuro-inflammatory reactions, (4) altered production of cytokines, and (5) enteric flora, including Helicobacter pylori. Longer term (chronic) injury involves not only these acute phenomena but also alterations in growth factors and stem cells and the occurrence of complex immuno-inflammatory reactions. In IBD, these alterations are driven by altered T-cell populations and pathological organisms (e.g. Mycobacterium paratuberculosis in Crohn’s disease). An impressive array of strategies have and are being developed to prevent these conditions. Most have focussed on manipulating the mediators, cytokines, growth factors and cells participating in the pathology of these states. For the NSAIDs, procedures have been developed which minimize the occurrence of gastroduodenal mucosal injury (e.g. cyclo-oxygenase-II specific drugs; carboxyl and alkyl nitrite esters; compounds with prostaglandin analogues, micronutrients or other anti-ulcer drugs). Some specific agonists, antagonists or enzymes regulators participating in these reactions have been developed which have impressive actions in animal and human models. However, in some conditions, multivalent drugs may prove more successful, reflecting the multiplicity of factors and cells involved in GI pathologies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gilinsky NH. Peptic ulcer disease in the elderly. Gastroenterol Clin N Am. 1990;19:255–71.
Corinaldesi R, De Giorgio R, Paternicõ A, Stanghellini V. Asymptomatic peptic ulcer disease. Is it worth looking for? Drugs. 1991;41:821–4.
Hencerson BE, Ross RK, Pike MC. Toward the primary prevention of cancer. Science. 1991;254:1131–8.
Monteiro E, Tavarela Veloso F, eds. Inflammatory bowel diseases. New insights into mechanisms of inflammation and challenges in diagnosis and treatment. Lancaster: Springer Science+Business Media Dordrecht; 1995.
Walsh JH. Unanswered questions about Helicobacter pylori. Ailment Pharmacol Ther. 1995;9 (Suppl. 1):31–7.
Hung RH, Tytgat GNJ, eds. Helicobacter pylori. Basic Mechanisms to Clinical Cure. Dordrecht, Boston, London: Springer Science+Business Media Dordrecht; 1994.
Matysiak-Budnik T, Megraud F. Helicobacter pylori in eastern European countries: what is the current status? Gut. 1994;35:1683–6.
Misiewicz JJ. Current insights in the pathogenesis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995;7:701–3.
Borén S, Normark S, Falk P. Helicobacter pylori: molecular basis for host recognition and bacterial adherence. Trends Microbiol. 1994;2:221–8.
Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120kDa protein, peptic ulceration, and gastric pathology. Lancet. 1991;338:332–5.
Mazzucchelli L, Wilder-Smith CH, Ruchti C, Meyer-Wyss B, Merki HS. Gastrospirillum hominis in asymptomatic, healthy individuals. Dig Dis Sci. 1993;38:2087–9.
Taha AS, Russell RI. Helicobacter pylori and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease. Gut. 1993;34:580–3.
El-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995;.109:681–91.
Taha AS, Dahill S, Nakshabendi I, Lee FD, Sturrock RD, Russell RI. Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs. Gut. 1993;34:1162–6.
Sanderson JD. Environmental factors - bacterial infection: Crohn’s disease and Mycobacterium paratuberculosis. In: Monteiro E, Tavarela Veloso F, eds. Inflammatory bowel diseases. New insights into mechanisms of inflammation and challenges in diagnosis and treatment. Dordrecht, Boston, London: Springer Science+Business Media Dordrecht; 1995:86–90.
Travis SPL. Mycobacteria on trial: guilty or innocent in the pathogenesis of Crohn’s disease? Eur J Gastroenterol Hepatol. 1995;7:1173–6.
Jewell DP. Pathogenesis of Crohn’s disease: the environment revisited. Eur J Gastroenterol Hepatol. 1995;7:383–4.
Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol. 1996;12:327–33.
Farmer RG, Michener WM. Association of inflammatory bowel diseases in families. Front Gastrointest Res. 1986;11:17–26.
Satsangi J, Jewell DP. Genetic markers in inflammatory bowel disease. Curr Opin Gastroenterol. 1996;12:322–6.
Rainsford KD, Quadir M. Gastrointestinal damage and bleeding from non-steroidal anti-inflammatory drugs. 1. Clinical and epidemiological aspects. Inflammopharmacology. 1995;3:169–90.
Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1988;24 (Suppl. 163):9–16.
Rainsford KD. Mechanisms of gastrointestinal ulceration from non-steroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Side-effects of anti-inflammatory drugs - 3. Lancaster: Springer Science+Business Media Dordrecht; 1992:97–114.
Rainsford KD. Mode of action, uses and side-effects of anti-rheumatic drugs. In: Rainsford KD, ed. Advances in anti-rheumatic therapy. Boca Raton: CRC Press; 1996:59–111.
Rainsford KD. Introduction to advances in anti-rheumatic therapy. In: Rainsford KD, ed. Advances in anti-rheumatic therapy. Boca Raton: CRC Press; 1996:1–10.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Rainsford, K.D. (1997). Emerging Research in Gastrointestinal Diseases. In: Mózsik, G., Nagy, L., Pár, A., Rainsford, K.D. (eds) Cell Injury and Protection in the Gastrointestinal Tract. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5392-8_1
Download citation
DOI: https://doi.org/10.1007/978-94-011-5392-8_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6268-8
Online ISBN: 978-94-011-5392-8
eBook Packages: Springer Book Archive